Treatment of hepatitis B virus: an update

被引：21

作者：

Ward, Haley ^{[1
]}

Tang, Lydia ^{[2
]}

Poonia, Bhawna ^{[2
]}

Kottilil, Shyam ^{[2
]}

机构：

[1] NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA

[2] Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, Baltimore, MD 21201 USA

来源：

FUTURE MICROBIOLOGY | 2016年 / 11卷 / 12期

关键词：

cccDNA; eradication; HBV; hepatitis B; Toll-like receptors; TLRs; ALPHA-GLUCOSIDASE INHIBITORS; CLOSED CIRCULAR DNA; PLASMACYTOID DENDRITIC CELLS; COMPLEX THERAPEUTIC VACCINE; ZINC-FINGER NUCLEASES; TERM-FOLLOW-UP; SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; IMMUNE-RESPONSES; IN-VIVO;

D O I：

10.2217/fmb-2016-0128

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse. Several novel therapeutic strategies are being researched and studied in clinical trials. Here we review these novel strategies to achieve sustained cure or elimination of HBV. These strategies include the targeting of the host or viral factors required for viral persistence as well as therapeutic vaccines.

引用

页码：1581 / 1597

页数：17

共 168 条

[1] Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
Agarwal, Kosh
Fung, Scott K.
Nguyen, Tuan T.
Cheng, Wendy
Sicard, Eric
Ryder, Stephen D.
Flaherty, John F.
Lawson, Eileen
Zhao, Sally
Subramanian, G. Mani
McHutchison, John G.
Gane, Edward J.
Foster, Graham R.
[J]. JOURNAL OF HEPATOLOGY, 2015, 62 (03) : 533 - 540
[2] Pathogen recognition and innate immunity
Akira, S
Uematsu, S
Takeuchi, O
[J]. CELL, 2006, 124 (04) : 783 - 801
[3] Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection
Al-Mahtab, M.
Bazinet, M.
Vaillant, A.
[J]. JOURNAL OF CLINICAL VIROLOGY, 2015, 69 : 228 - 228
[4] Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg plus Chronic Hepatitis B Infection
Al-Mahtab, Mamun
Bazinet, Michel
Vaillant, Andrew
[J]. PLOS ONE, 2016, 11 (06):
[5] Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B
Al-Mahtab, Mamun
Akbar, Sheikh Mohammad Fazle
Aguilar, Julio Cesar
Uddin, Md. Helal
Khan, Md. Sakirul Islam
Rahman, Salimur
[J]. HEPATOLOGY INTERNATIONAL, 2013, 7 (04) : 981 - 989
[6] HLA AND HEPATITIS-B INFECTION
ALMARRI, A
BATCHELOR, JR
[J]. LANCET, 1994, 344 (8931) : 1194 - 1195
[7] An Bao-yan, 2007, Zhonghua Gan Zang Bing Za Zhi, V15, P729
[8] A Common HLA-DPA1 Variant is a Major Determinant of Hepatitis B Virus Clearance in Han Chinese
An, Ping
Winkler, Cheryl
Guan, Li
O'Brien, Stephen J.
Zeng, Zheng
[J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (07) : 943 - 947
[9] IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
Belloni, Laura
Allweiss, Lena
Guerrieri, Francesca
Pediconi, Natalia
Volz, Tassilo
Pollicino, Teresa
Petersen, Joerg
Raimondo, Giovanni
Dandri, Maura
Levrero, Massimo
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (02) : 529 - 537
[10] T cell receptor-therapy in HBV-related hepatocellularcarcinoma
Bertoletti, Antonio
Brunetto, Maurizia
Maini, Mala K.
Bonino, Ferruccio
Qasim, Waseem
Stauss, Hans
[J]. ONCOIMMUNOLOGY, 2015, 4 (06):

← 1 2 3 4 5 6 7 8 9 10 →